Today: 10 June 2026
Tesla stock price slides today as Trump tariff turmoil hits markets — and EV demand worries return
23 February 2026
2 mins read

Tesla stock price slides today as Trump tariff turmoil hits markets — and EV demand worries return

New York—February 23, 2026, 10:10 EST. Regular session on the board.

  • Tesla shares slipped roughly 2% in early New York action, lagging behind a milder start for U.S. markets.
  • Fresh worries over tariffs and new doubts about U.S. EV demand, traders said, were in play.
  • Nvidia’s results are up next on Feb. 25, with investors also looking for clarity on the timing of the new tariffs.

Tesla (TSLA.O) slipped 2.2% Monday, echoing a broader risk-off tone as fresh demand worries resurfaced for the electric-vehicle maker. Shares shed $9.18, trading at $402.64 during the morning session.

Stocks slipped out of the gate, with the Dow down 0.18% after President Donald Trump imposed a fresh 15% tariff, a move that followed the Supreme Court’s rejection of his earlier, broader levies. The S&P 500 edged lower by 0.12%, and the Nasdaq dropped 0.20%.

Tesla’s timing is key here. Shares have a habit of whipping around as risk sentiment changes, and the market hasn’t quite nailed down demand in the U.S. now that incentives have faded from the EV landscape.

“The tariff landscape is now more uncertain than before, uncertainty is not good news for any economy or market,” said Rodrigo Catril, senior FX strategist at NAB. Tomas Hildebrandt, senior portfolio manager at Evli, put it more bluntly: “Trump is Trump – he won’t abandon his America-first mantra and will keep pushing the limits as long as he’s in power.” Reuters

There’s data backing up the demand concerns. In January, U.S. new EV sales came in at an estimated 66,276 units, Cox Automotive said in a Feb. 16 report—a drop of 29.9% from the prior year. EVs grabbed just about 6% of new-vehicle sales for the month. Tesla moved roughly 40,100 units in January, enough to push its market share up to 60.5%, but volume still fell 17% from December, according to the same report. Inventories of new EVs stretched out to 168 days’ supply, based on the current sales pace. Average transaction prices for Teslas dipped 2%, landing at $52,628.

Federal incentives are out of the picture, and the U.S. market is still recalibrating. Congress’s broad legislative move struck down the $7,500 tax credit for new EV leases and purchases, along with the $4,000 used EV credit—both ending as of Sept. 30, 2025, according to Reuters.

Auto stocks showed a mixed picture. Rivian shed 0.9%, Ford edged down 0.6%, and General Motors was off by roughly 1%. Lucid, on the other hand, tacked on about 1%.

Autonomy remains part of the story. On Monday, Reuters pointed out that most driver-assist features on the road, including Tesla’s Full Self-Driving, still sit at Level 2 — they’ll handle steering and braking, but drivers can’t tune out. Level 3, where “eyes-off” becomes possible, is only an option in certain scenarios. “We don’t know if Level 3 ever makes financial sense,” said Paul Thomas, head of Bosch’s North America division. Former Waymo chief John Krafcik put it bluntly: for many customers, “the juice isn’t worth the squeeze.” Reuters

The move isn’t one-sided. Pinning down a tariff timeline might give risk assets some footing, but if demand keeps slipping, pressure on EV prices could mount, squeezing margins across the whole sector.

The focus shifts to Wednesday, Feb. 25, with Nvidia scheduled to release quarterly numbers at 2 p.m. PT (5 p.m. ET)—a moment that could sway sentiment across the tech sector. Tesla, for its part, has a history of moving in tandem with broader tech risk when the tape gets volatile.

Stock Market Today

  • SenSen Networks Limited (ASX:SNS) Shows Potential Undervaluation Amid Positive Earnings Outlook
    June 10, 2026, 5:44 PM EDT. SenSen Networks Limited (ASX:SNS) has experienced a 10% share price increase recently yet still trades below its yearly highs. The company's price-to-earnings (PE) ratio stands at 13.31x, significantly below the software industry average of 25.62x, suggesting potential undervaluation. SenSen's high beta indicates notable price volatility, providing additional buying opportunities. The firm's earnings growth is projected in the teens over the coming years, signaling robust future cash flows and a promising outlook. Investors may find value in accumulating more shares as the market may not fully price in this growth. However, considerations around the company's financial health remain crucial before investment decisions.

Latest articles

YY Group Shares Spike as Humanoid Robot Plans Unveiled

YY Group Shares Spike as Humanoid Robot Plans Unveiled

10 June 2026
YY Group Holding shares surged to $0.165 on heavy volume after announcing a commercial humanoid-robotics initiative using Unitree G1 robots and facility-management data, reframing the company as a robotics-and-AI data play; the rally comes despite 2025 net loss, dilution risk from a relaunched at-the-market share-sale program, and no disclosed robot-related revenue or contracts.
Snap Inc. Targets Health Ad Dollars With New Snapchat Study as Pressure Builds

Snap Shares Drop Again With Tech Names Under Pressure

10 June 2026
Snap Inc. shares slid 4% to $5.38, extending a three-day losing streak and deepening doubts about its turnaround despite improved cash flow and cost cuts, as investors await CEO Evan Spiegel’s June 16 AWE keynote and weigh weak ad growth, falling eCPMs, and ongoing macro and regulatory risks.
Outlook Therapeutics Gains as FDA Timeline for Lytenava Comes Up

Outlook Therapeutics Gains as FDA Timeline for Lytenava Comes Up

10 June 2026
Outlook Therapeutics soared 26% to $0.89 on heavy volume as investors zeroed in on the FDA’s 60-day review window for Lytenava after a successful appeal, but risks remain with the stock still under $1, looming Nasdaq compliance deadlines, and warnings of possible dilution and going-concern doubts if FDA approval or favorable labeling isn’t secured soon.
CrowdStrike stock steadies premarket after Anthropic’s Claude Code Security rattles cyber shares
Previous Story

CrowdStrike stock steadies premarket after Anthropic’s Claude Code Security rattles cyber shares

Eli Lilly stock pops after Novo trial miss, new Zepbound pen gets FDA nod
Next Story

Eli Lilly stock pops after Novo trial miss, new Zepbound pen gets FDA nod

Go toTop